ライフサイエンスコーパス: cardiac pacemaker

1 tion in the mouse sinoatrial node (SAN), the cardiac pacemaker.

2 hat GATA6 may be a potential modifier of the cardiac pacemaker.

3 a novel, completely self-contained leadless cardiac pacemaker.

4 insights into the integrative action of the cardiac pacemaker.

5 d channel (HCN) 4 is a major subunit for the cardiac pacemaker.

6 erlying the age-related deterioration of the cardiac pacemaker.

7 uashing the age-related deterioration of the cardiac pacemaker.

8 ous renal replacement therapy, and permanent cardiac pacemaker.

9 hts into the unique molecular make-up of the cardiac pacemaker.

10 perioperative management among patients with cardiac pacemakers.

11 r cardiovascular electronic devices, such as cardiac pacemakers.

12 hanges from 40 to 120 ms in 19 subjects with cardiac pacemakers.

13 can interfere with the function of implanted cardiac pacemakers.

14 s, including deep-brain stimulators(1,2) and cardiac pacemakers(3).

15 y effectors in beta-adrenergic regulation of cardiac pacemaker activity and can sustain positive chro

16 that CaMKII plays a vital role in regulating cardiac pacemaker activity mainly via modulating I(Ca, L

17 r times to activate and sustain the putative cardiac pacemaker activity of the terminal chamber syner

18 activated cation (HCN) ion channels underpin cardiac pacemaker activity, but their role in smooth mus

19 on channels are well established to underlie cardiac pacemaker activity, their role in smooth muscle

20 siological processes, including neuronal and cardiac pacemaker activity, vascular smooth muscle contr

21 types, as HCN and TTC channels also mediate cardiac pacemaker activity.

22 ed cation channel that mediates neuronal and cardiac pacemaker activity.

23 ) that contributes pivotally to neuronal and cardiac pacemaker activity.

24 to the diastolic depolarization critical for cardiac pacemaker activity.

25 HCN4 function and could cause a reduction of cardiac pacemaker activity.

26 he inward and outward channels that underlie cardiac pacemaker activity.

27 ulas; cardiac surgery, including implantable cardiac pacemaker and coronary artery bypass surgery; an

28 atrial node (SAN) to function as the leading cardiac pacemaker and the atrioventricular (AV) junction

29 f the 1998 guideline for the implantation of cardiac pacemakers and antiarrhythmia devices.

30 Many cardiac pacemakers and defibrillators are not approved b

31 e of moderate intensity in all patients with cardiac pacemakers and focally increased uptake of mild

32 Worldwide, nearly 3 million patients have cardiac pacemakers and more than 300,000 have implantabl

33 Cardiac pacemakers and reservoirs of central venous line

34 ectromagnetic interference may occur between cardiac pacemakers and wireless hand-held (cellular) tel

35 Conventional cardiac pacemakers are associated with several potential

36 The current cardiac pacemakers are battery dependent, and the pacing

37 Cardiac pacemakers are limited by device-related complic

38 tion age of various Pu materials (Pu powder, cardiac pacemaker battery, (242)Cm heat source, etc.) wa

39 ble, coupled-clock system that drives normal cardiac pacemaker cell automaticity.

40 s) from sarcoplasmic reticulum (SR) regulate cardiac pacemaker cell function by activation of electro

41 tracellular Ca(2+) cycling dynamics regulate cardiac pacemaker cell function on a beat-to-beat basis

42 Cardiac pacemaker cells (CPCs) rhythmically initiate the

43 cluding generating electrical rhythmicity in cardiac pacemaker cells and diverse types of brain neuro

44 rate that a Pak1 signaling pathway exists in cardiac pacemaker cells and that this novel pathway play

45 These findings suggest that cardiac pacemaker cells are physically segregated and mo

46 Cardiac pacemaker cells autonomously generate electrical

47 Sinoatrial node myocytes (SAMs) act as cardiac pacemaker cells by firing spontaneous action pot

48 Sinoatrial node myocytes act as cardiac pacemaker cells by generating spontaneous action

49 Cardiac pacemaker cells create rhythmic pulses that cont

50 al. (2019) identify the embryonic origin of cardiac pacemaker cells in zebrafish and implicate Wnt5b

51 support the idea that Ca(2+) regulates CL in cardiac pacemaker cells on a beat-to-beat basis, and sug

52 echanisms driving heart rate acceleration in cardiac pacemaker cells remain incompletely understood.

53 many natural and technological systems, from cardiac pacemaker cells to coupled lasers.

54 ors (10 lines) were selectively expressed in cardiac pacemaker cells, cardiomyocytes, vascular endoth

55 In cardiac pacemaker cells, hetero-tetramer GIRK1/4 channel

56 ired for heat-triggered rate acceleration in cardiac pacemaker cells, isolated hearts and in vivo.

57 body, including thalamocortical neurons and cardiac pacemaker cells.

58 ls modulate the firing rates of neuronal and cardiac pacemaker cells.

59 f several types of ion channels expressed in cardiac pacemaker cells.

60 inate key insights into the formation of the cardiac pacemaker-conduction system, heart valves and at

61 The sinoatrial node (SAN), the primary cardiac pacemaker, consists of a head domain and a junct

62 The cardiac pacemaker controls the rhythmicity of heart cont

63 ilitating diseases, including heart failure, cardiac pacemaker defects, muscle wasting, and osteoporo

64 ld be used as a pulse generator, mimicking a cardiac pacemaker delivering pulses of 10muA for 0.5ms a

65 ensable for proximal limb, craniofacial, and cardiac pacemaker development.

66 tients (15%) required the use of >1 leadless cardiac pacemaker during the procedure.

67 a leadless, battery-free, fully implantable cardiac pacemaker for postoperative control of cardiac r

68 ells (such as stem cell-derived neuronal and cardiac pacemakers) for gene- and cell-based therapies.

69 nt and is crucial for both basal and reserve cardiac pacemaker function.

70 hMSCs transfected with a cardiac pacemaker gene, mHCN2, by electroporation expres

71 Thyroid hormone regulation of the cardiac pacemaker gene, the hyperpolarization-activated

72 ss rate was 94%: for patients whose leadless cardiac pacemaker had been implanted for <6 weeks (acute

73 tely self-contained, single-chamber leadless cardiac pacemaker has shown to be safe and feasible.

74 pacemaker was developed, the basic design of cardiac pacemakers has remained relatively unchanged ove

75 Leadless cardiac pacemakers have emerged as a safe and effective

76 multicenter trials, who received a leadless cardiac pacemaker implant and who subsequently underwent

77 ment (TAVR), mitral valve clip implantation, cardiac pacemaker implantation, and atrial fibrillation/

78 chronic retrieval (>6 weeks) of the leadless cardiac pacemaker in humans.

79 dy, we implanted an active-fixation leadless cardiac pacemaker in patients who required permanent sin

80 ique for epicardial implantation of wireless cardiac pacemakers in adult rats that has lower mortalit

81 e) with a mean age of 63 years and permanent cardiac pacemakers in situ were studied.

82 921) was 72% compared with 92.5% for the 179 Cardiac Pacemaker, Inc.

83 Proper expression and function of the cardiac pacemaker is a critical feature of heart physiol

84 The leadless cardiac pacemaker is a pioneering device for heart patie

85 A leadless cardiac pacemaker (LCP) system was recently introduced t

86 s including medical tubing, Foley catheters, cardiac pacemaker leads, and soft robots on massive scal

87 The leadless cardiac pacemaker met prespecified pacing and sensing re

88 ytes were used as two- and three-dimensional cardiac pacemaker models.

89 sing system can be used to build an adaptive cardiac pacemaker modulating the heart rate with respect

90 It is unknown whether cardiac pacemakers or permanent central venous catheters

91 excitable cells modulate the excitability of cardiac pacemaker preparations by two distinct mechanism

92 to canonical Wnt5b signaling to initiate the cardiac pacemaker program, including activation of pacem

93 Using a model of TF-induced cardiac pacemaker reprogramming, we conclusively establi

94 irected differentiation into specific mature cardiac, pacemaker, smooth muscle, and endothelial cell

95 roviding potential strategies for biological cardiac pacemaker therapy.

96 Temporary cardiac pacemakers used in periods of need during surgic

97 A cardiac pacemaker was implanted during the first two wee

98 atic and potentially lifesaving therapies of cardiac pacemakers while mitigating many of the risks as

99 crossover study, we tested 980 patients with cardiac pacemakers with five types of telephones (one an